PMID- 30936931
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1735-5362 (Print)
IS  - 1735-9414 (Electronic)
IS  - 1735-5362 (Linking)
VI  - 14
IP  - 1
DP  - 2019 Feb
TI  - Regulatory effects of hemp seed/evening primrose oil supplement in comparison 
      with rapamycin on the expression of the mammalian target of rapamycin-complex 2 
      and interleukin-10 genes in experimental autoimmune encephalomyelitis.
PG  - 36-45
LID - 10.4103/1735-5362.251851 [doi]
AB  - The mammalian target of rapamycin (mTOR) signaling plays a critical role in lipid 
      synthesis and immune responses. The T regulatory cells (Treg) as suppressor of T 
      cells, are a subset of T cells that modulate the immune system, maintain 
      tolerance, and prevent autoimmune diseases.. The interleukin (IL) -10 derived 
      from the Treg and T helper (Th) 2 is an anti-inflammatory cytokine in multiple 
      sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Due to the 
      exclusive roles of rapamycin (RAPA) in mTOR inhibition, we evaluated the 
      regulatory effect of the hemp seed oil/evening primrose oil (HSO/EPO) supplement 
      in comparison with RAPA in EAE. EAE was induced by using myelin oligodendrocyte 
      glycoprotein peptide and complete freund's adjuvant (CFA) in C57BL/6 mice, total 
      mRNA was extracted from local lymph nodes and real-time polymerase chain reaction 
      was used to evaluate the expression level of the rapamycin-insensitive companion 
      of mTOR complex 2 (RICTOR) and IL-10 genes. The expression of IL-10 and RICTOR 
      genes were significantly increased in HSO/EPO group. In contrast with RAPA 
      groups, histological findings have shown that the HSO/EPO treated group 
      remarkably reduced cell infiltration and promoted remyelination. The EPO/HSO has 
      beneficial effects on the repair of myelin, which was confirmed by immunological 
      and histological findings.
FAU - Rezapour-Firouzi, Soheila
AU  - Rezapour-Firouzi S
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine 
      Institute, Urmia University of Medical Sciences, Urmia, I.R. Iran.
FAU - Kheradmand, Fatemeh
AU  - Kheradmand F
AD  - Solid Tumor Research Center, Urmia University of Medical sciences, Urmia, I.R. 
      Iran.
FAU - Shahabi, Shahram
AU  - Shahabi S
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine 
      Institute, Urmia University of Medical Sciences, Urmia, I.R. Iran.
FAU - Tehrani, Ali Asghar
AU  - Tehrani AA
AD  - Department of Pathobiology, Faculty of Veterinary Medicine, Urmia University, 
      Urmia, I.R. Iran.
FAU - Mazloomi, Ebrahim
AU  - Mazloomi E
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine 
      Institute, Urmia University of Medical Sciences, Urmia, I.R. Iran.
FAU - Mohammadzadeh, Adel
AU  - Mohammadzadeh A
AD  - Departement of Immunology and Genetics, Faculty of Medicine, Urmia University of 
      Medical Sciences, Urmia, I.R. Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Res Pharm Sci
JT  - Research in pharmaceutical sciences
JID - 101516968
PMC - PMC6407336
OTO - NOTNLM
OT  - Autoimmune encephalomyelitis
OT  - Demyelination
OT  - Immune tolerance
OT  - Lymph node
OT  - Rapamycin
EDAT- 2019/04/03 06:00
MHDA- 2019/04/03 06:01
PMCR- 2019/02/01
CRDT- 2019/04/03 06:00
PHST- 2019/04/03 06:00 [entrez]
PHST- 2019/04/03 06:00 [pubmed]
PHST- 2019/04/03 06:01 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - RPS-14-36 [pii]
AID - 10.4103/1735-5362.251851 [doi]
PST - ppublish
SO  - Res Pharm Sci. 2019 Feb;14(1):36-45. doi: 10.4103/1735-5362.251851.